BearingPoint//Beyond Announces its Infonova Digital Business Platform Is Now 5G-ready
BearingPoint//Beyond today announced that its Infonova Digital Business Platform is now 5G-ready, enabling Communication Service Providers (CSPs) around the world to create, experiment, launch and monetize new 5G offerings at speed and at scale. The Infonova platform has already been selected by major CSPs, including NTT Group and Tata Communications.
As 5G rolls out across the globe, new opportunities emerge for CSPs and their partners to develop new business models, use cases and applications that make use of 5G’s high-speed, low latency and always-on mobile connectivity. However research has demonstrated that, in order to succeed in the multi-trillion dollar enterprise services market, CSPs must adopt leaner, more agile operations that prioritize experimentation, collaboration, innovation, and rapid time to market.
To monetize 5G at scale, CSPs must ensure that their operational and business support systems can meet four main requirements:
- Orchestration and delivery of complex solutions spanning both different types of networks (e.g: 4G, Fiber,5G) and different sources of services (e.g. edge, AR, VR)
- Flexibility in charging and monetization capabilities enabling CSPs to bundle and price anything from network slicing and consumer IoT, to industrial IoT solutions
- The development of partner ecosystems enabling CSPs to truly co-invent and co-create joint solutions with multiple third parties that better fit customer needs
- Increased operational agility and speed with cloud native solutions
The 5G-ready Infonova Digital Business Platform has been designed to deliver precisely these capabilities, enabling CSPs to:
- Reduce risk by rapidly experimenting, launching and monetizing new offerings and scale with success, due to its SaaS delivery model
- Achieve fast and simple integration with their business and operational landscape by using a comprehensive library of Open APIs and a flexible microservices and containerized architecture delivered in cloud native environments
- Offer advanced charging and billing capabilities ready to support any pricing model, including network slicing offerings
- Bundle anything with connectivity – especially important for consumer IoT, OTT services and enterprise solutions (e.g. Industrial IoT, Autonomous driving) – as a result of its flexible catalogue
- Access comprehensive order management and service fulfillment functionalities, managing the challenge and complexity of dynamic 5G service activation, diversity of devices and network functions
- Support multiple business partners on a single platform, allowing CSPs to easily and dynamically exchange offerings, orchestrate and monetize B2B2X, B2B, IoT marketplace, B2C and wholesale 5G use cases with an ecosystem of partners
“If CSPs are to capitalize on 5G opportunities – especially those presented by the multi-trillion-dollar enterprise services market - they need to start embracing digital business platforms. These platforms enable them to create new B2B2x business models with partner ecosystems, packaging 5G connectivity with devices, applications, IoT capabilities and AI into entirely new products and services,” said Angus Ward, CEO of BearingPoint//Beyond. “Our Infonova Digital Business Platform helps CSPs do just that. By using our platform, CSPs can roll out new, complex, partner-driven offerings quickly and reach new lucrative vertical sectors and customers.”
“IDC believes that multi-partner relationships are a growing domain in the digital world and will need platforms such as BearingPoint//Beyond’s digital business platform to orchestrate and monetize them effectively,” commented Mark Thomason, Research Director, IDC Digital Business Models and Monetization.
For more information on how BearingPoint//Beyond can help you monetize 5G, please click here.
- ENDS -
BearingPoint//Beyond is a BSS and digital platform solution provider helping businesses to innovate and grow revenue in face of digital disruption.
Using the SaaS-based Infonova digital platform, BearingPoint//Beyond gives organizations the ability to experiment, launch and monetize new offerings at speed, with minimum risk and cost. Building connections between technologies and partners, enabling them to collaborate, co-innovate and expand their reach with an ecosystem of partners. Bringing them closer to their customers, helping you drive higher efficiency and automation, and becoming more agile in the face of competition.
BearingPoint//Beyond is part of BearingPoint.
BearingPoint is an independent management and technology consultancy with European roots and a global reach. The company operates in three business units: The first unit covers the advisory business with a clear focus on five key areas to drive growth across all regions. The second unit provides IP-driven managed services beyond SaaS and offers business critical services to its clients supporting their business success. The third unit provides the software for successful digital transformation and regulatory requirements. It is also designed to explore innovative business models with clients and partners by driving the financing and development of start-ups and leveraging ecosystems.
BearingPoint’s clients include many of the world’s leading companies and organizations. The firm has a global consulting network with more than 10,000 people and supports clients in over 75 countries, engaging with them to achieve measurable and sustainable success.
For more information, please visit:
BearingPoint//Beyond home page: https://www.bearingpointbeyond.com
Annual Report: www.bearingpoint.com/en/about-us/annual-report/
Press contact BearingPoint//Beyond
Head of Marketing
Phone: + 44 (0)79 6637 1449
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ESMO 2020: Cabometyx® (cabozantinib) in Combination With Opdivo® (nivolumab) Demonstrates Significant Survival Benefits in Patients With Advanced Renal Cell Carcinoma in Pivotal Phase III CheckMate -9ER Trial19.9.2020 19:30:00 EEST | Press release
Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced the first presentation of results from the pivotal Phase III CheckMate -9ER trial, in which Cabometyx® (cabozantinib) in combination with Bristol Myers Squibb’s Opdivo® (nivolumab) demonstrated significant improvements across all efficacy endpoints, including overall survival (OS), in previously untreated advanced renal cell carcinoma (RCC).1 Cabometyx® in combination with Opdivo® reduced the risk of death by 40% versus sunitinib (HR: 0.60 [98.89% Confidence Interval [CI]: 0.40–0.89]; p= 0.0010; median OS not reached in either arm). In patients receiving Cabometyx® in combination with Opdivo®, median progression-free survival (PFS), the trial’s primary endpoint, was doubled compared to those receiving sunitinib alone: 16.6 months versus 8.3 months respectively (Hazard Ratio [HR]: 0.51 [95% CI 0.41–0.64], p < 0.0001). In addition, Cabometyx® in combination with Opdivo® demonstrated a superior objective response rate, wit
Takeda Presents New Data Highlighting Scientific Advancements in Lung Cancer at ESMO Virtual Congress18.9.2020 13:55:00 EEST | Press release
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the company is presenting data from its lung cancer portfolio at the virtual European Society for Medical Oncology (ESMO) conference. Notably, insights from sub-analyses of the Phase 3 ALTA 1L study reinforce both the compelling evidence of intracranial efficacy with ALUNBRIG® (brigatinib) as a first-line treatment for patients with anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) as well as associated quality of life (QoL) data. Takeda is also featuring updated 10-month follow-up results from the Phase 1/2 trial of mobocertinib (TAK-788), demonstrating mobocertinib achieved a duration of response (DoR) of more than one year in the trial’s study population of patients with epidermal growth factor receptor (EGFR) Exon20 insertion+ metastatic NSCLC (mNSCLC). “We’re pleased to present our ongoing research in lung cancer at this year’s virtual ESMO congress, including new
Incyte Announces Encouraging Results From Phase 2 Trial of Retifanlimab (INCMGA0012) in Patients With Previously Treated, Advanced Squamous Cell Carcinoma of the Anal Canal18.9.2020 13:00:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced results from its Phase 2 POD1UM-202 trial evaluating retifanlimab, a PD-1 inhibitor, in previously treated patients with advanced squamous cell carcinoma of the anal canal (SCAC) who have progressed following standard platinum-based chemotherapy. The trial enrolled 94 patients, including those with well-controlled human immunodeficiency virus (HIV) infection (10%). Retifanlimab monotherapy resulted in a confirmed objective response rate (ORR) of 14% as determined by independent central review (ICR) using RECIST v1.1. Responses were observed regardless of PD-L1 status, presence of liver metastases, age or HIV+ status. Retifanlimab was generally well-tolerated with a safety profile as expected of a PD-1 inhibitor and no loss of HIV infection control. Key findings from POD1UM-202: N=94 ORR* (95% CI) 13.8% (7.6-22.5) Best OR*, n 1 CR 12 PR 33 SD DCR 48.9% DOR, median (95% CI), months 9.5 (5.6-NE) PFS, median (95% CI), months 2.3 (1.9-3.6) OS, median (95
Sigfox and Cube Infrastructure Managers Announce Major Partnership in IoT Infrastructure18.9.2020 10:30:00 EEST | Press release
Sigfox, the global 0G network1 and cloud provider for industrial data, is proud to announce a new strategic alliance with Cube Infrastructure Managers (Cube), through the sale of its German 0G network to Cube. Sigfox has grown its 0G IoT services by rolling out 0G networks across 72 countries and regions, which was largely achieved with partners called Sigfox Operators. These operators are the owners of the 0G networks, which they operate as exclusive connectivity providers of Sigfox IoT services, offering worldwide connectivity to customers. The sale of the German network to Cube will allow Sigfox to finance its continued innovation efforts in data value extraction and improvements in cloud algorithms to reduce energy consumption and allow the implementation of even more cost-effective devices and sensors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200918005116/en/ Cube Infrastructure Managers, the European infrastructu
Sensorion successfully raises approximately €31 (US$ 36.5) million in an oversubscribed private placement to US and European investors18.9.2020 09:00:00 EEST | Press release
Regulatory News: Not for release, publication or distribution, directly or indirectly, in or into the United States, Canada, Australia or Japan. This press release is not intended as an offer and is for informational purpose only Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN – the “Company”) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders announces today the success of its previously announced capital increase. The Company has placed 18,236,000 new ordinary shares with a nominal value of €0.10 each (the “New Shares”), for total gross proceeds of approximately € 31 million by means of an accelerated bookbuild offering to the benefit of categories of persons (the “Reserved Offering”). The issue price of the New Shares is €1.70 per share, representing a 3.5% discount to the weighted average share price on the day preceding the date on which the issuance price
ESMO 2020: Phase II CLARINET FORTE Results Show Increasing Dose Frequencies of Somatuline® Autogel® (lanreotide) Allows Patients with NETs to Delay Treatment Escalation by up to 8.3 Months18.9.2020 08:00:00 EEST | Press release
Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced the release of first efficacy and safety data from the CLARINET FORTE study, with the abstract to be presented as a mini-oral presentation at the 2020 European Society for Medical Oncology (ESMO) Congress, taking place virtually from 19-21 September 2020. The prospective single-arm, open-label, exploratory, international Phase II study investigated the efficacy and safety of increasing the dose frequency of Somatuline® Autogel ® (lanreotide) in patients with pancreatic or midgut NETs with centrally-assessed progression within the last two years while on a standard lanreotide regimen for ≥24 weeks. An extension of progression-free survival (PFS) rates and encouraging disease-control rates (DCR) were recorded in both tumor types, with no new safety signals. “These results support a clinically meaningful benefit to a population of patients with high unmet medical need by potentially delaying escalation to more toxic treatm
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom